Tags: Alzheimer's/Dementia | Alzheimers | drug | crenezumab | brain

New Alzheimer's Drug May Help Mildly Impaired


Researchers say an experimental drug from the biotech company Genentech failed to slow mental decline in tests on more than 500 people with mild to moderate Alzheimer's disease.
The drug did show some promise in the least-impaired participants who received the higher of two doses in the mid-stage studies.

The drug, crenezumab (cruh-NEZ-oo-mab), aims to clear away the sticky amyloid plaques clogging Alzheimer's patients' brains.

The company says it is encouraged by the possible benefit for mildly impaired patients and will talk with regulators about the next steps to test the drug.

Results were discussed Wednesday at the Alzheimer's Association International Conference in Copenhagen.
 

© Copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

1Like our page
2Share
Health-News
Researchers say an experimental drug from the biotech company Genentech failed to slow mental decline in tests on more than 500 people with mild to moderate Alzheimer's disease. The drug did show some promise in the least-impaired participants who received the higher of two...
Alzheimers, drug, crenezumab, brain
104
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved